Syndax Pharmaceuticals, Inc. (SNDX)
SNDX Stock Price Chart
Explore Syndax Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze SNDX price movements and trends.
SNDX Company Profile
Discover essential business fundamentals and corporate details for Syndax Pharmaceuticals, Inc. (SNDX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Mar 2016
Employees
270.00
Website
https://www.syndax.comCEO
Michael A. Metzger
Description
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
SNDX Financial Timeline
Browse a chronological timeline of Syndax Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is -$0.45, while revenue estimate is $79.27m.
Earnings released on 30 Apr 2026
EPS came in at -$0.48 surpassing the estimated -$0.59 by +18.64%, while revenue for the quarter reached $64.86m , missing expectations by -7.02%.
Earnings released on 26 Feb 2026
EPS came in at -$0.78 falling short of the estimated -$0.58 by -33.55%, while revenue for the quarter reached $68.73m , beating expectations by +6.88%.
Earnings released on 3 Nov 2025
EPS came in at -$0.70 surpassing the estimated -$0.74 by +5.41%, while revenue for the quarter reached $45.87m , missing expectations by -27.58%.
Earnings released on 4 Aug 2025
EPS came in at -$0.83 surpassing the estimated -$1.00 by +17.00%, while revenue for the quarter reached $37.96m , missing expectations by -16.85%.
Earnings released on 5 May 2025
EPS came in at -$0.98 surpassing the estimated -$1.04 by +5.77%, while revenue for the quarter reached $20.04m , beating expectations by +8.06%.
Earnings released on 3 Mar 2025
EPS came in at -$1.10 falling short of the estimated -$1.08 by -1.85%, while revenue for the quarter reached $7.68m , missing expectations by -39.93%.
Earnings released on 5 Nov 2024
EPS came in at -$0.98 surpassing the estimated -$1.13 by +13.27%, while revenue for the quarter reached $12.50m , missing expectations by -89.15%.
Earnings released on 1 Aug 2024
EPS came in at -$0.80 surpassing the estimated -$0.91 by +12.09%, while revenue for the quarter reached $3.50m .
Earnings released on 8 May 2024
EPS came in at -$0.85 surpassing the estimated -$0.96 by +11.46%.
Earnings released on 27 Feb 2024
EPS came in at -$1.00 falling short of the estimated -$0.99 by -1.01%, while revenue for the quarter reached $536.00k .
Earnings released on 2 Nov 2023
EPS came in at -$0.73 surpassing the estimated -$0.80 by +8.75%.
Earnings released on 3 Aug 2023
EPS came in at -$0.64 surpassing the estimated -$0.73 by +12.33%.
Earnings released on 8 May 2023
EPS came in at -$0.59 surpassing the estimated -$0.61 by +3.28%.
Earnings released on 28 Feb 2023
EPS came in at -$0.62 surpassing the estimated -$0.64 by +3.13%.
Earnings released on 3 Nov 2022
EPS came in at -$0.58 surpassing the estimated -$0.65 by +10.77%.
Earnings released on 8 Aug 2022
EPS came in at -$0.62 surpassing the estimated -$0.65 by +4.62%.
Earnings released on 9 May 2022
EPS came in at -$0.63 matching the estimated -$0.63.
Earnings released on 1 Mar 2022
EPS came in at $1.81 surpassing the estimated $0.28 by +546.43%, while revenue for the quarter reached $126.58m , beating expectations by +1.91k%.
Earnings released on 15 Nov 2021
EPS came in at -$0.40 surpassing the estimated -$0.64 by +37.50%, while revenue for the quarter reached $12.38m , beating expectations by +3.25%.
Earnings released on 9 Aug 2021
EPS came in at -$0.44 surpassing the estimated -$0.74 by +40.54%, while revenue for the quarter reached $379.00k , meeting expectations.
SNDX Stock Performance
Access detailed SNDX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
